What AI MVP Development Means in a Clinical Context
An AI MVP in healthtech is not the same as an AI MVP in any other sector. The minimum viable product must include more than the core AI capability. It must include the safety mechanisms, the audit trail, the explainability features, and the data governance controls that make it safe to use in a clinical environment, even at MVP stage. This is not a compliance burden to manage around. It is what makes the product trustworthy to the clinicians you need to win over and to the NHS procurement teams who will evaluate whether to deploy it. Clinical AI products typically fall into one of a few regulatory categories under MHRA guidance. Software intended to diagnose, prevent, monitor, treat, or alleviate disease is likely to be a medical device and subject to MHRA registration. Software that supports clinical decision-making by providing information, without making the decision itself, may fall outside the medical device definition but still faces DTAC assessment for NHS deployment and NHS Digital Data Security and Protection Toolkit requirements if it handles NHS patient data. The distinction between these categories has significant implications for what the MVP must include and how long regulatory validation will take. We help you identify which category your product falls into during scoping, before you have committed to an architecture. Getting this wrong early is expensive. The EU AI Act adds a further dimension for products sold into EU markets. Healthcare AI systems that assist in clinical decision-making are likely to be classified as high-risk under Annex III, requiring conformity assessment, technical documentation, and registration in the EU AI Act database before being placed on the EU market. We include an EU AI Act risk classification assessment in healthtech engagements as standard.
Our Delivery Process for Clinical AI MVPs
We start every healthtech engagement with a regulatory scoping session alongside the technical scoping. This session establishes the intended purpose of the product, the intended user (clinician, patient, administrator), the clinical context of use, whether the product falls under MHRA medical device regulations, the DTAC domains relevant to the product, and the NHS data security requirements that apply if the product will access NHS patient data. This regulatory scoping is a prerequisite for the technical scoping, because the architecture decisions are different for a product that faces MHRA registration than for one that does not, and different again for a product that accesses NHS systems versus one that runs on data the NHS trust provides in a batch. The technical scoping session then covers the core AI capability, the data sources the model requires, the explainability requirements for clinician-facing outputs, the audit trail requirements for clinical governance, and the data residency requirements for patient data. For NHS-facing products, data must typically remain within UK-based infrastructure, which affects the model provider choices and the deployment architecture. Development includes building the AI capability with the explainability layer from the start. A clinical AI output that cannot tell the clinician why it produced that output is not trustworthy and will not be adopted. Explainability is not a feature to add later. It is a design constraint. Safety mechanisms including confidence thresholds below which the AI defers to a human, output validation against clinical range constraints, and mandatory human review for high-stakes outputs are built into the architecture from the first sprint.
Deliverables for a Clinical AI MVP
At handover, you receive the AI MVP deployed on UK-based infrastructure, with full source code, clinical AI documentation, and regulatory support materials. The clinical AI documentation covers the model architecture and the data it was trained or fine-tuned on, the validation approach and the performance metrics on clinically relevant test sets, the explainability mechanism and how it translates model behaviour into clinician-readable reasoning, the safety mechanisms and their configuration, and the audit trail structure. This documentation is designed to be provided to NHS clinical governance teams, DTAC assessors, and MHRA reviewers. It is written in the language that these audiences use, not in generic AI engineering documentation language. GDPR Article 9 compliance documentation covers the legal basis for processing special category health data, which for clinical AI is most commonly research or healthcare purposes under Schedule 1 of the Data Protection Act 2018 rather than consent. The ICO guidance on AI and data protection is addressed in the privacy impact assessment template included in the handover. The audit trail implementation logs every AI output alongside the input data and the explainability output, with a retention policy aligned to clinical record-keeping requirements. This log is queryable by your clinical governance team and can be exported for MHRA or DTAC review. NHS Digital Data Security and Protection Toolkit requirements relevant to the product's data handling are documented, with gaps identified and addressed where they fall within the scope of the MVP.
Timeline for a Clinical AI MVP
Two to three weeks for a scoped clinical AI MVP. The scope in a healthtech context is more tightly defined than in other sectors because the regulatory constraints reduce the range of acceptable architecture options. This actually helps with timeline predictability: there are fewer decision branches when the constraints are clear. Week one covers the data pipeline from the clinical data source to the AI model, the core AI capability, and the initial explainability implementation. By the end of week one, the AI produces outputs with associated explanations on the clinical dataset you have provided for development. Week two covers the safety mechanisms, the audit trail, the user interface for clinician-facing products, and GDPR controls for patient data. By the end of week two, the product operates with the full safety and governance layer in place. Week three covers the regulatory documentation, the NHS data security controls, performance testing on the clinical dataset, and the handover walkthrough. The timeline assumes you have access to a representative sample of the clinical data the model will use in production. If data access is constrained, we can scope the MVP around synthetic or anonymised data initially, with a documented path to production data once the necessary data sharing agreements are in place. NHS Digital guidance on data sharing agreements and data processing frameworks is incorporated into this planning where relevant.
MHRA, DTAC, and NHS Compliance Built In
The regulatory landscape for clinical AI in the UK involves three primary frameworks that may apply simultaneously, depending on your product's intended purpose and deployment context. MHRA medical device regulations apply to software that meets the definition of a medical device, including software that diagnoses, prevents, monitors, or treats disease. If your product meets this definition, it needs to be registered with the MHRA before being placed on the UK market. The registration pathway depends on the risk class of the device, which is determined by the intended purpose and the clinical context of use. We help you assess whether your product meets the medical device definition and, if it does, which risk class applies. DTAC, the Digital Technology Assessment Criteria, applies to digital health products being considered for adoption by NHS organisations. DTAC covers clinical safety, data protection, technical security, interoperability, and usability. A product that fails DTAC assessment will not be adopted by NHS trusts regardless of its clinical effectiveness. We design the MVP against DTAC's five domains from the start, producing the evidence documents that DTAC assessors look for. NHS Digital Data Security and Protection Toolkit requirements apply to organisations that access NHS patient data. If your product connects to NHS systems or processes data provided by an NHS organisation, you will need to complete the DSP Toolkit assessment. We identify the Toolkit assertions relevant to your product and implement the technical controls they require. The EU AI Act adds requirements for products sold into EU markets, with healthcare AI likely to be classified as high-risk. We include EU AI Act compliance documentation for founders with EU market ambitions.
Why Healthtech Founders Choose SpeedMVPs
Healthtech founders come to SpeedMVPs because they need an AI development partner that understands the clinical and regulatory context, not just the technology. Most AI agencies can build a capable AI model. Very few understand what DTAC requires, what the MHRA expects from a medical device software manufacturer, or how to design a clinical AI audit trail that meets NHS clinical governance standards. These are the capabilities that determine whether a technically excellent clinical AI product gets adopted or gets blocked at procurement. We also understand the commercial dynamics of healthtech. NHS procurement cycles are long and the evaluation criteria are demanding. The product you are building now will face that scrutiny, and the architectural decisions you make at MVP stage will either make that scrutiny manageable or create expensive rework at the point where you can least afford it. We have seen both outcomes and we design the architecture to navigate towards the first. Our fixed-price model gives you cost certainty in a sector where development costs are hard to predict due to regulatory requirements. Our two-to-three-week delivery gives you a working product to put in front of NHS clinical champions before your funding requires you to show progress. Our full code ownership transfer means your clinical IP belongs to you from day one. Get a free consultation at speedmvps.co.uk